Skip to search formSkip to main contentSkip to account menu

ZD 2767

Known as: ZD-2767, ZD2767, ZD2767P 
A phenol mustard glutamate prodrug which induces apoptosis by cross-linking DNA and with potential use in Antibody Directed Enzyme Prodrug Therapy… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Prodrug‒carboxypeptidase G2 (e.g., ZD2767P+CPG2) can realize a targeted treatment where the specific advantage is a lack of CPG2… 
Highly Cited
2007
Highly Cited
2007
We have designed a targeted systemic suicide gene therapy that combines the advantages of tumor-selective gene expression, using… 
Highly Cited
2005
Highly Cited
2005
PURPOSE Antibody-directed enzyme prodrug therapy (ADEPT) requires highly selective antibody-mediated delivery of enzyme to tumor… 
Highly Cited
2002
Highly Cited
2002
Antibody-directed enzyme prodrug therapy is a targeted therapy in which a prodrug is activated selectively at the tumour site by… 
2001
2001
An antibody-directed enzyme prodrug therapy (ADEPT) system against CEA-positive tumours is currently in phase I clinical trials… 
2001
2001
ZD2767P is a phenol mustard glutamate prodrug which is currently being developed for Antibody Directed Enzyme Prodrug Therapy… 
2000
2000
ZD2767P, a nitrogen mustard glutamate prodrug, is currently being evaluated in Phase 1 clinical trials of antibody directed… 
Highly Cited
1995
Highly Cited
1995
Sixteen novel potential prodrugs derived from phenol or aniline mustards and their 16 corresponding drugs with ring substitution…